Tianhong Li

Trials

Studies that name Tianhong Li as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:24 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07859592 · Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma

  VA Office of Research and Development · not yet recruiting · Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm · principal investigator
• Ph1
  NCT06352359 · Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

  OncoC4, Inc. · recruiting · Advanced Solid Tumor · principal investigator
• Ph3
  NCT05671510 · ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

  OncoC4, Inc. · active not recruiting · Non Small Cell Lung Cancer · principal investigator
• Ph1/Ph2
  NCT05101356 · A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

  University of California, Davis · suspended · Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma · principal investigator
• Ph1/Ph2
  NCT04552704 · CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

  Tianhong Li · terminated · Advanced Malignant Solid Neoplasm · principal investigator
• Ph1/Ph2
  NCT04140526 · Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

  OncoC4, Inc. · active not recruiting · Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 07:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Targeting Integrins in Lung Cancer
  I01BX003895 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · fiscal years 2021 to 2024
  Same name and institution; not confirmed by an ID
• First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
  R44CA250824 · NCI · ONCOC4, INC. · fiscal years 2021 to 2022 · $1,000,000 awarded in 2022
  Grant number is on one of their registry trials

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• I01RD001080
  RePORTER returned no project for this number; it is shown as the registry gives it.
  Named on NCT07859592
• Integrated Cancer Biology Program
  P30CA093373 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Wolf-Dietrich Heyer · fiscal years 2004 to 2026
  Named on NCT05101356, NCT04552704